Relmada’s New Plan: Execution Is the Story
Q2 call pivots from data to manufacturing as IND timing slips and a new CBO takes charge.
RLMD · Earnings Call · 2026-08-06
Relmada’s Q2 2026 call was less about new clinical data and more about the mechanics of getting NDV-01 to the registrational starting line. The company says it has achieved clear plan status on manufacturing, but the timeline for the Phase III RESCUE program has slipped from “mid-2026” to filing the IND by year-end. CEO Sergio Traversa framed the delay as a scheduling problem, not a science problem: “There was really nothing unexpected. It's just everything in manufacturing, until you have done and you are to the final, you never know.” — Sergio Traversa, Chief Executive Officer · 2026-08-06 He added that the biggest hurdle is just getting a GMP slot with contract manufacturer Piramal. That nuance matters: it means the company has not identified a technical failure, but investors are still pricing in the calendar slip.
The call also marked a leadership transition. New Chief Business Officer Bipin Dalmia, who led the U.S. launch of the first FDA-approved intravesical gene therapy for NMIBC, gave his first public assessment. His presence signals Relmada is already thinking about commercialization even before the pivotal trial starts. Dalmia’s pitch centers on ease of use — a sustained-release gel that can be instilled in an office setting in roughly 5 minutes, versus conventional Gem/Doce that requires a specialized pharmacy and up to four hours of chair time. “It's just a matter of execution now.” — Bipin Dalmia, Chief Business Officer · 2026-08-06 he said, echoing the operational tenor of the call.
This is a notable shift from prior quarters, when management talked about data cadence and CDMO readiness. In November 2025, Raj Pruthi said the plan was to “initiate both of these trials... at about the same time in 2026.” — Raj S. Pruthi, Head of Clinical Program · 2025-11-13 In May 2026, he hoped to share “a handful of patients maybe by the end of this calendar year” — Raj S. Pruthi, Urologic Oncologist · 2026-05-12 with three-month CR data. Now Sergio says the first meaningful data could come in the first half of 2027, and they may prefer six-month data over three-month because of retreatment dynamics. The operational narrative is tightening, but it is also being pushed out.
The new voice and the commercial thesis
Dalmia’s addition is the most concrete strategic change. He brings 30 years in uro-oncology and a track record of value creation, and he has already taken ownership of the non-muscle-invasive bladder cancer (non muscle) franchise. His first task is to translate the Phase II data—95% CR at any time and 76% durable CR at 12 months—into a FDA alignment story that distinguishes NDV-01 from competitors like TAR-200 and cretostimogene. The company is positioning itself not as a me-too intravesical, but as a simpler, more durable option that works in both BCG-unresponsive and, eventually, intermediate-risk and BCG-naive settings. The regulatory path is clear: FDA has agreed to two registration pathways, with a primary endpoint of CR at any time plus duration of response. That flexibility is a competitive advantage, but it also means investors need to trust the company's interpretation of “totality of the data.” The AdCom read-through from a competitor product was deliberately left ambiguous, with management noting only that FDA has not fixed a numeric response-rate threshold.Money is not the problem; credibility is
Financially, Relmada is in its best position in years. It ended Q2 with $217.7 million in cash, and management says that funds operations through 2029, including the Phase III RESCUE program. That extends the runway well past the initial readout. Cash runway of ~15.5 quarters at the June close, up from 3 quarters a year earlier gives the company the luxury to execute without a near-term capital raise. R&D expense for the quarter was $8.4 million, up from $2.8 million year-over-year, driven by NDV-01 and sepranolone study costs and higher manufacturing/storage costs. Yet the stock has been bleeding: down 36.5% over the past 90 days, with a peak-to-trough drawdown of 41%. That suggests the market is not giving full credit for the balance sheet strength. The likely culprit is the IND timing. When a small biotech pushes its pivotal trial start from mid-2026 to end-of-year, the market naturally wants to see proof that the schedule is real.Sergio’s closing line is a confidence statement, but it will take the actual IND filing to reset the narrative. The broader market context is no help. While many of today’s reporters are grappling with tariff refund dynamics—a theme echoing through the global keyword trajectory—Relmada is a pure-play biotech with no tariff exposure. Its story is idiosyncratic, which is either a blessing (no macro headwind) or a curse (no sector tailwind). For a stock that has been in a prolonged drawdown, the distinction matters. In short, what changed at Relmada is not the science—it remains promising—but the operating cadence. The company is betting that a new CBO, a cash buffer, and a tightened focus on manufacturing will convert a promising asset into a registrational program. Investors will be watching the IND filings and the first Phase III data with both hope and skepticism.We know what is in front of us, we have a clear plan, and we have the team and the resources to deliver.